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18F-FDG PET versus 
18F-FDG PET/CT for
Adrenal Gland Lesion Characterization: 
a Comparison of Diagnostic Efficacy in
Lung Cancer Patients
Objective: The aim of this study was to assess the diagnostic efficacy of inte-
grated PET/CT using fluorodeoxyglucose (FDG) for the differentiation of benign
and metastatic adrenal gland lesions in patients with lung cancer and to compare
the diagnostic efficacy with the use of PET alone.
Materials and Methods: Sixty-one adrenal lesions (size range, 5 104 mm;
mean size, 16 mm) were evaluated retrospectively in 42 lung cancer patients.
Both PET images alone and integrated PET/CT images were assessed, respec-
tively, at two-month intervals. PET findings were interpreted as positive if the
FDG uptake of adrenal lesions was greater than or equal to that of the liver, and
the PET/CT findings were interpreted as positive if an adrenal lesion show attenu-
ation > 10 HU and showed increased FDG uptake. Final diagnoses of adrenal
gland lesions were made at clinical follow-up (n = 52) or by a biopsy (n = 9) when
available. The diagnostic accuracies of PET and PET/CT for the characterization
of adrenal lesions were compared using the McNemar test.
Results: Thirty-five (57%) of the 61 adrenal lesions were metastatic and the
remaining 26 lesions were benign. For the depiction of adrenal gland metastasis,
the sensitivity, specificity, and accuracy of PET were 74%, 73%, and 74%,
respectively, whereas those of integrated PET/CT were 80%, 89%, and 84%,
respectively (p values; 0.5, 0.125, and 0.031, respectively).
Conclusion: The use of integrated PET/CT is more accurate than the use of
PET alone for differentiating benign and metastatic adrenal gland lesions in lung
cancer patients.
drenal metastases are frequently noted in patients with lung cancer (1);
however, the majority of adrenal lesions are likely to be benign, even in
lung cancer patients (2 5). The reported incidence of adrenal lesions in
lung cancer patients, regardless as to whether they are due to metastasis, varies from
4% to 18% in clinical studies (3, 6, 7), and up to 40% of these lesions may be
malignant and present as solitary sites of metastasis (8). Therefore, it is essential to
differentiate between benign and malignant lesions in lung cancer patients to ensure
optimal management. The percutaneous biopsy is the gold standard for confirming the
status of adrenal lesions, but is invasive and difficult to perform, and thus frequently
leads to complications or study failure (9).
Noninvasive imaging methods have been examined in terms of their abilities to
determine adrenal lesion status. Chemical shift MR imaging is found to be useful for
differentiating between benign and malignant adrenal lesions (10, 11). CT has proven
useful in this context because of its ability to measure attenuation, on both
unenhanced images and on delayed contrast-enhanced images (12 14). The use of
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A18Fluorine-fluorodeoxyglucose (FDG) PET has also shown
encouraging results (15 20), but relatively few studies
have addressed the usefulness of FDG PET for evaluating
adrenal lesions specifically in patients with lung cancer (15,
16, 19).
Recently, the development of integrated PET/CT has
allowed functional PET and anatomical CT images to be
obtained in one session. The combination of PET and CT
data sets using the integrated PET/CT approach is not
additive; in fact, it is highly synergistic (21 23). The
limited ability of PET to localize accurately lesions, due to
a lack of precise anatomical landmarks, has been
demonstrated by several studies (24 28). However,
several recent studies on the accuracy of PET/CT versus
PET have shown that PET/CT helps resolve this problem
for ambiguous lesions, especially for anatomy-related
lesions (26, 29 33). However, no study has yet addressed
the usefulness of integrated PET/CT for differentiating
benign and metastatic adrenal lesions in lung cancer
patients. Our goal was to assess the diagnostic efficacy of
integrated 
18F-FDG PET/CT for the differentiation of
benign and metastatic adrenal gland lesions in lung cancer




Our institutional review board approved this research
study. Patient informed consent was not required for the
retrospective study, but written informed consent was
obtained from all patients for obtaining the integrated FDG
PET/CT study.
Patients and the Characteristics of Adrenal Lesions
From May 2003 to July 2005, we treated 53 lung cancer
patients with uncharacterized adrenal lesion(s) detected by
contrast-enhanced thoracic (covering from thoracic inlet to
middle portion of both kidneys) CT. During the same
period, 1,283 new lung cancer patients were registered at
our institution. An adrenal gland lesion was considered
present when a round or oval lesion (short- and long-axis
diameters were within a factor of 1.5 of each other) with a
discrete margin was identified in the adrenal gland. When
diffuse enlargement without nodule formation was identi-
fied, the abnormality was considered hyperplastic and was
not included. Patients that had undergone integrated
PET/CT were studied before the initiation of chemother-
apy or radiation therapy to avoid any potential effects of
the therapies as seen by adrenal 
18F-FDG uptake. Eleven of
the 53 patients were excluded because of a short clinical
follow-up period of < 6 months for nine patients and
follow-up loss for two patients. Therefore, we included 42
patients (38 men and 4 women; age range 33 77 years;
mean  standard deviation [SD], 62  8.9 years).
Of these 42 patients, 38 underwent PET/CT once. The
38 patients had a total of 52 adrenal gland lesions; 26
patients had a single unilateral adrenal gland lesion, 10
patients had two lesions (one each lesion in each gland)
bilaterally, and two patients had three lesions (one in one
gland and two in the other gland), also bilaterally. Four
patients underwent FDG PET/CT twice at intervals of two
months for two patients, of an interval of 11 months in one
patient, and an interval of 14 months in the remaining one
patient. In one of these four patients, a unilateral lesion
was present at the initial study and bilateral lesions were
detected at the follow-up study. Therefore, counting the
adrenal lesions in each study, nine lesions (six from three
patients and three from one patient) from these four
patients were also included in the study. Including the nine
lesions in these four patients, 61 adrenal lesions in 42
patients were the targets of this study.
Histological analyses showed that the primary lung
cancers were adenocarcinomas in 24 patients, squamous
cell carcinomas in 15 patients, small cell carcinomas in two
patients, and a large cell neuroendocrine carcinoma in one
patient. A total of 61 adrenal lesions in 42 patients were
evaluated using contrast-enhanced standalone CT reports.
All patients underwent integrated PET/CT for the primary
tumor characterization and the staging of histologically-
proven lung cancer.
The final diagnoses of adrenal lesions were reached by
clinical follow-ups (n = 52) or by histopathological
examinations (n = 9) of surgical specimens, when available.
In the clinical follow-up studies, an adrenal lesion was
considered benign if it did not show any change in size for
at least six months (mean  SD for 20 presumed benign
adrenal lesions, 14  7 months; range, 6 28 months;
median, 12 months). A lesion was considered malignant if
it showed an increase or decrease in size after treatment
( 3 mm change in the longest diameter).
Integrated PET/CT Acquisition
All patients fasted for at least six hours before the
PET/CT examination, although oral hydration with
glucose-free water was allowed. After ensuring a normal
blood glucose level in the peripheral blood, patients
received an intravenous injection of 370 MBq (10 mCi) of
FDG and then rested for approximately 45 minutes before
scanning. Scans were acquired using a PET/CT device
(Discovery LS; GE Medical Systems, Milwaukee, WI),
which consisted of a PET scanner (Advance NXi; GE
Medical Systems) and an eight-section CT scanner
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systems were mechanically aligned such that a patient
could be moved from the CT scanner to the PET scanner
gantry by moving the examination table by 68 cm.
CT was performed from the head to the pelvic floor
according to a standardized protocol using the following
settings: 140 kVp; 80 mA; tube rotation time, 0.5 seconds
per rotation; pitch, 6; and section thickness, 5 mm (to
match the PET section thickness). Patients maintained
normal shallow respiration during the acquisition of CT
scans. Iodinated contrast material was not administered.
Immediately after the unenhanced CT scan, an emission
PET scan was performed in the identical transverse field of
view. The acquisition time for PET was 5 minutes per table
position (each frame). The CT data were resized from a
512  512 matrix to a 128  128 matrix to match the
PET data so that scans could be fused and CT-based
transmission maps generated. PET data sets were
reconstructed iteratively using an ordered subset expecta-
tion maximization algorithm with segmented attenuation
correction (two iterations, 28 subsets) using the CT data.
Co-registered scans were displayed using eNTEGRA
software (GE Medical Systems).
18F-FDG PET and 
18F-FDG PET/CT Image
Interpretation
One nuclear medicine physician with 12 years of PET
interpretation experience and two years of experience of
integrated PET/CT analysis and one radiologist with 16
years of CT experience and two years of experience of
integrated PET/CT analysis that were unaware of previous
contrast-enhanced CT findings, evaluated the imaging
findings twice. Interpretations were performed once with
the PET images only and subsequently with the integrated
PET/CT images. Decisions on findings were reached by
consensus. First, the two observers interpreted the
dedicated PET images in a random order without observ-
ing the CT component of integrated PET/CT. Two months
later, the same nuclear medicine physician and radiologist
evaluated the integrated PET/CT images.
When interpreting the dedicated PET images, special
attention was given to FDG uptake in the region of the
adrenal glands. PET findings were interpreted as positive if
the FDG uptake of an adrenal lesion was greater than or
equal to that of the liver. PET findings were interpreted as
negative if the FDG uptake of the adrenal mass was less
than that of the liver. Because the liver was often inhomo-
geneous in FDG uptake, we chose the visual average (the
highest and lowest) of liver uptake for comparison.
According to previous studies (15, 17), visual assessment
of suspected lesions was just as effective at differentiating
active from inactive disease as quantitative analysis using a
standardized uptake value (SUV). Therefore, the
maximum SUV was not used to differentiate benign and
malignant adrenal lesions.
When interpreting the integrated PET/CT images, we
also assessed CT component of the adrenal lesions in
addition to the PET component of the lesions. The longest
diameter of adrenal lesion was measured where it
appeared largest on the transverse images. We also
recorded the attenuation value of the adrenal lesions. A
region of interest, ovoid or circular, covering between one-
half to two-thirds of the largest area within the adrenal
lesion, was selected. For each of the adrenal lesions,
average attenuation values (mean of two measurements)
and SDs were obtained.
When lesions had  10 HU, all adrenal lesions, regard-
less of the FDG uptake value, were interpreted as benign.
When lesions had > 10 HU attenuation value, they were
regarded as metastatic with an FDG uptake greater than or
equal to that of the liver and as benign with an FDG
uptake less than that of the liver. After the image reading
sessions, maximum SUVs were recorded if the FDG uptake
of the adrenal lesion was considered present at the
integrated PET/CT examination. The nodule sizes of the
benign and metastatic adrenal lesions were also recorded.
Statistical Analysis
The accuracies, sensitivities, and specificities of PET and
PET/CT for the diagnosis of adrenal metastases were
assessed using a generalized estimating equation. We
regarded each case in which there was agreement between
the final diagnosis and the image interpretation as positive,
and similarly, each case in which there was disagreement
as negative. The diagnostic accuracies of both methods for
the diagnosis of adrenal metastasis were compared using
the McNemar test. Differences in the maximum SUVs, the
nodule sizes, and attenuation values of benign and
metastatic adrenal lesions were calculated using the
student’s t test. P values of < 0.05 were considered to
indicate statistical significance. These calculations were
performed using a statistical software package (SPSS for
Windows; SPSS Inc., Chicago, IL).
The causes, sizes, and maximum SUV values of the false
positive and false negative interpretations for both the PET
and integrated PET/CT findings were retrospectively
assessed.
RESULTS
The sizes of the adrenal lesions on CT scans ranged from
5 to 104 mm in the longest diameter, with a mean of 16
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Benign versus Malignant Adrenal Lesions
Thirty-five (57%) of the 61 adrenal lesions eventually
were proved to be metastatic adrenal disease, either by
surgery (n = 3) or clinical follow-up (n = 32). The remain-
ing 26 adrenal lesions were benign, as determined either
by surgery (n = 6) or by at least six months of clinical
follow-up (n = 20). Histopathological examinations of the
benign adrenal lesions demonstrated the presence of
adenomas (n = 5) and endothelial cysts (n = 1). Overall, the
mean sizes ( SD) of the 61 adrenal lesions were 16  15
mm (range; 5 104 mm). The mean lesion sizes ( SD)
were 13  8 mm for the benign lesions and 18  17 mm
for the malignant lesions (p = 0.187) (Table 1). The mean
attenuation values ( SD) were 12.4  11.1 for the
benign lesions and 29.7  10.9 for the malignant lesions (p
Sung et al.
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Fig. 1. A false-positive interpretation with the use of PET only, but
a true negative interpretation with the use of integrated PET/CT in
a 57-year-old man with adenocarcinoma in the right upper lobe of
the lung.
A. PET demonstrates increased uptake (arrow) in the right adrenal
gland area with a maximum standardized uptake value of 3.2. PET
alone regarded the uptake as positive.
B. Unenhanced CT scan shows hepatic cysts (arrowheads).
C. On an integrated PET/CT image, the uptake (arrow) falls on the
liver, thus enabling a correct interpretation as negative uptake in
the right adrenal gland.
Table 1. Size Distribution of the Malignant and Benign Adrenal Gland Lesions and the Correctly Diagnosed Rates According to
the Sizes Determined by the Use of PET Alone and with Integrated PET/CT
Malignant (n = 35) Benign (n = 26)
Size Range < 10 mm* 10 mm  D < 20 mm 20 mm < 10 mm 10 mm  D < 20 mm 20 mm
+ Total
(n = 9) (n = 16) (n = 10) (n = 15) (n = 7) (n = 4)
PET alone 4/9 (44%) 12/16 (75%) 10/10 (100%) 11/15 (73%) 5/7 (71%) 3/4 (75%) 45/61 (74%)
Integrated PET/CT 4/9 (44%) 14/16 (88%) 10/10 (100%) 14/15 (93%) 5/7 (71%) 4/4 (100%) 51/61 (84%)
Note. At PET, *a nodule as small in its longest diameter of 5 mm was correctly diagnosed as malignant and 
+a nodule as large in its longest diameter of 
38 mm was correctly diagnosed as benign. D = diameter< 0.001), and the mean maximum SUV ( SD) values
were 1.7  1.84 for the benign lesions and 7.2  5.13 for
the malignant lesions (p < 0.001).
Diagnostic Efficacy of PET alone versus Integrated
PET/CT
The sensitivity, specificity, positive predictive value,
negative predictive value, and accuracy of PET for the
detection of metastatic disease were 74% (26 of 35
lesions), 73% (19 of 26 lesions), 79% (26 of 33 lesions),
68% (19 of 28 lesions), and 74% (45 of 61 lesions), respec-
tively. The corresponding values for sensitivity, specificity,
positive predictive value, negative predictive value, and
accuracy for PET/CT were 80% (28 of 35 lesions), 89%
(23 of 26 lesions), 90% (28 of 31 lesions), 77% (23 of 30
lesions), and 84% (51 of 61 lesions), respectively. Thus,
the accuracy for PET/CT (84%, 51 of 61 lesions) was
significantly higher than that for PET (74%, 45 of 61
lesions) (p = 0.031). However, the values of sensitivity (p =
0.5) and specificity (p = 0.125) for PET/CT were not signif-
icantly different from the values for PET.
Causes of False Lesion Interpretations
For the PET images alone, seven false positive interpre-
tations were made for two adenomas that were proven at
surgery, for one endothelial cyst that was proven at
surgery, for two misinterpretations of hepatic uptakes as
adrenal gland uptakes (Fig. 1), and for two misinterpreta-
tions of lymph node uptakes as adrenal gland uptakes. For
nine false negative interpretations made, the mean size and
mean maximum SUV value of the adrenal lesions were 8
mm (range, 5 13 mm) and 1.6 (range, 0 4.5), respec-
tively (Table 1).
For the integrated PET/CT images, three false positive
interpretations were made, and these stemmed from two
adrenal adenomas (Fig. 2) and one endothelial cyst (Fig. 3)
in the adrenal glands. For the seven false negative interpre-
tations made, the mean size and mean maximum SUV
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Fig. 2. A false-positive interpretation by the use of both PET and
PET/CT in a 33-year-old woman with an adrenal adenoma that
was confirmed by surgical excision. The patient also had an
adenocarcinoma in the left lower lobe of the lung.
A. PET demonstrates increased uptake (arrow) in the left adrenal
gland lesion with a maximum standardized uptake value of 4.6.
B. An unenhanced CT scan shows a 14 mm sized nodule (arrow)
in the left adrenal gland.
C. Integrated PET/CT shows high uptake (arrow) in the nodule of
the left adrenal gland.value were 7 mm (range, 5 11 mm) and 1.0 (range, 0
2.4), respectively (Table 1).
PET and PET/CT made six discordant interpretations. In
four cases, PET produced a false-positive result because
FDG uptake in the liver or lymph nodes was misinter-
preted as adrenal uptake. In one case in which a patient
underwent FDG PET/CT twice with a two-month interval,
false-negative results we obtained by PET and by PET/CT
at the initial study. However, at the follow-up study, PET
continued to show a false-negative result, but PET/CT
produced a true-positive result. In this particular case, the
adrenal lesion was 6 mm in diameter as determined at the
initial study and 11 mm in diameter as determined at the
second study. In the remaining single case, a nodule was
regarded as benign by PET as the adrenal uptake was
interpreted as uptake in the adjacent left kidney, whereas
it was correctly interpreted as metastasis by the use of
integrated PET/CT (Fig. 4).
DISCUSSION
CT is the primary diagnostic imaging method for adrenal
gland lesion evaluation. Lipid within adenomas causes low
attenuation in unenhanced CT images. In addition,
adenomas demonstrate rapid washout after intravenous
contrast administration (12 14). The sensitivity and
specificity of unenhanced CT (at a threshold attenuation of
10 HU) for distinguishing an adenoma from other
diseases has been determined as 79% and 96%, respec-
tively (13). The sensitivity, specificity, and diagnostic
accuracy as reported by a dynamic study were 98%, 92%,
and 96%, respectively (12).
Signal intensity on T2-weighted and chemical shift
imaging using signal intensity reductions between in-phase
and opposed-phase MR images were initially investigated
in an effort to differentiate benign from malignant lesions.
However, benign and malignant lesions were found to
Sung et al.
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Fig. 3. A false-positive interpretation by the use of both PET and
PET/CT in a 56-year-old woman with an endothelial cyst that was
confirmed by surgical excision. The patient also had a squamous
cell carcinoma in the left lower lobe of the lung. 
A. PET demonstrates increased uptake (arrow) in the left adrenal
gland lesion with a maximum standardized uptake value of 4.3.
B. An unenhanced CT scan shows a 7 mm sized nodule (arrow) in
the left adrenal gland.
C. Integrated FDG PET/CT shows high uptake (arrow) in the
nodule of the left adrenal gland.overlap considerably in terms of signal intensity (10, 11,
34). Burt et al. (8) reported a false-positive level for unilat-
eral adrenal masses of 67% in patients with operable non-
small cell lung cancer, i.e., 14 of 21 histologically benign
masses were interpreted as malignant masses based on the
relative signal strengths of T1- and T2-weighted images.
Unlike CT and MRI, FDG PET intensities are dependent
on the glucose metabolism in the malignant lesions. FDG
PET in patients with lung cancer and adrenal masses has
reported ranges for sensitivities of 93 100%, specificities
of 80 100%, and diagnostic accuracies of 92 100% (15-
20). However, the limited accuracy of lesion localization
using PET alone, due to the lack of precise anatomical
landmarks, has been demonstrated by several previous
studies (24 28).
Recently, integrated 
18F-FDG PET/CT was introduced.
This technique can produce directly functional PET and
anatomical CT images in one session. Integrated 
18F-FDG
PET/CT findings are not simply the summation of PET and
CT findings; in fact they are the result of a high level of
synergism between the two modalities (21 23). Previous
studies that have evaluated the accuracy of PET/CT versus
PET have shown that rate of ambiguous lesions findings is
lower for the use of PET/CT (26, 29 33). In the present
FDG PET versus FDG PET/CT for Adrenal Gland Lesion Characterization in Lung Cancer
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Fig. 4. A false-negative interpretation with the use of PET only, but a true positive interpretation with the use of integrated PET/CT in a
33-year-old woman with an adrenal metastasis confirmed by clinical follow-up. The patient also had adenocarcinoma in the right lower
lobe of the lung.
A. PET demonstrates increased uptake (arrow) in the left adrenal gland area with a maximum SUV of 3.5. Uptake was regarded as
benign by PET alone because the uptake was interpreted as left kidney uptake.
B. An unenhanced CT scan shows an 11-mm-sized nodule (arrow) in the left adrenal gland.
C. On an integrated PET/CT image, the uptake (arrow) falls on the left adrenal gland, thus enabling a correct interpretation as positive
uptake (uptake extent is equal to that of liver).
D. The nodule (arrow) in the left adrenal gland shows an increase in size at a 7-month follow-up CT. Hepatic metastasis is also noted
(arrowhead).
CDstudy, a statistically significant difference was found
between the accuracy of PET and of integrated PET/CT in
terms of differentiating benign and malignant adrenal
masses in patients with lung cancer.
In this study, the FDG uptake of an adrenal lesion was
compared with that of liver, thus an adrenal lesion was
interpreted as positive for metastasis if the FDG uptake
was greater or equal to that of the liver. However, Bagheri
et al. (35) addressed that normal adrenal glands show a
wide range of FDG uptake and can demonstrate uptake
equal to or slightly greater than liver activity. Recently,
Metser et al. (32) suggested that a maximum SUV of > 3.1
usefully differentiates malignant and benign adrenal
lesions. However, using a maximum SUV of 3.1 as a cutoff
for malignant adrenal nodule detection is only a guideline,
and care must be taken when the interpretation is based
solely on the SUVs as this approach may potentially lead
to a false negative study, especially for small sub-centime-
ter metastatic adrenal nodules.
Attenuation values of the adrenal lesion were also
evaluated on the CT component of the integrated PET/CT
images in this study. When lesions had  10 HU, all
adrenal lesions, regardless of the FDG uptake value, were
interpreted as benign. When lesions had > 10 HU attenua-
tion value, they were regarded as metastatic with the FDG
uptake was greater than in the liver and as benign with the
FDG uptake was less than in the liver. Interestingly, image
interpretations using an attenuation value combined with
FDG uptake were not different with image interpretations
only using FDG uptake. Moreover, the sensitivity and
specificity of the CT component of the integrated PET/CT
(at a threshold attenuation of  10 HU) for the diagnosis
of adrenal metastasis, excluding FDG uptake, were 94%
and 35%, respectively. These findings indicate a discrep-
ancy between the current and previously published studies
(13), namely, a relatively higher sensitivity and relatively
much lower specificity of the unenhanced CT. The discrep-
ancy may be explained by the use of different CT
techniques. In this study, attenuation values were
measured on the CT component of integrated PET/CT
images that were obtained using lower killovoltage (140
kVp) and milliamperage (80 mA) settings compared to the
settings employed for conventional CT techniques.
Therefore, beam-hardening artifacts more frequently
developed and the attenuation values of the adrenal
lesions were measured with higher values, especially for
the small sized adrenal lesions. We provisionally regarded
the CT component of the integrated PET/CT as not useful
for the diagnosis of adrenal metastasis.
In contrast to previously published studies for 
18F-FDG
PET, the present results showed a lower sensitivity,
specificity, and diagnostic accuracy. There are several
possible reasons to explain these results. First, the adrenal
lesions of relatively small sizes were included in this study;
the overall mean size ( SD) and median of 61 adrenal
lesions were 16  15 mm (range; 5 104 mm) and 13 mm,
respectively. In previous studies, the mean sizes of the
adrenal lesions were 20  10 mm (range; 5 42 mm) (18),
26 mm (range; 5 54 mm) (15), 24  16 mm (range; 6
110 mm) (32), and 20 mm (range; 5 95 mm) (33), respec-
tively. In this study, CT images were obtained using a
multi-detector row CT, which could provide much thinner-
section CT images and thus help detect small-sized adrenal
gland lesions. Previous studies (16 20) were performed
before the development of multi-detector row CT. Second,
we included cases of rather long mean follow-up periods,
thus, we might have more accurate reference standard
values. For example, in this study, 20 benign adrenal
lesions had a 14  7 month follow-up period.
Additionally, two malignant adrenal lesions, which were
erroneously diagnosed as benign by PET (with the use of
integrated PET/CT, one lesion was wrongly diagnosed and
the other was correctly diagnosed), showed a detectable
increase in their sizes at studies performed seven months
and 12 months after the initial studies, respectively. In
previous studies, their mean follow-up period for making a
benign diagnosis for the adrenal lesions could not be identi-
fied (15, 18).
The commonly reported causes of false-positive results
have been due to pheochromocytomas and benign
adenomas (18, 36). There were three cases of false-positive
findings shown by integrated PET/CT in the present study.
Two cases were due to benign adenomas and one case to
an endothelial cyst. The cause of the uptake in the
endothelial cyst was unclear.
Commonly reported causes of false-negative results are a
small lesion size, necrotic metastases, and metastases from
neuroendocrine tumors (18, 37). In the present study,
there were seven false-negative integrated PET/CT
interpretations, and all were due to small lesion size (range
5 11 mm; mean 7 mm).
One potential limitation of this study is that a biopsy was
not performed in all cases. Therefore, we may have missed
cases of micrometastasis or slow-growing metastatic lesions
in the adrenal gland. Moreover, there might have been
metastatic lesions that did not show any size change as
chemotherapy hampered lesion growth. This is an inherent
drawback in all studies of this type, because not all adrenal
lesions can be proven histopathologically. In addition,
cortisol, dehydroepiandrosterone, and sex hormone levels
were not determined to examine the possibility of stress-
induced adrenal activation.
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was found to provide 80% sensitivity, 89% specificity, and
84% accuracy for the characterization (metastatic versus
benign) of CT-positive adrenal gland lesions in lung cancer
patients, and was found to be more accurate than the use
of PET alone.
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